Bruce A. Cohen
Chief Executive Officer at Statim Pharmaceuticals, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jeffrey Schwartz | M | 45 | 6 years | |
| Kirk Dornbush | M | - |
Iconic Therapeutics, Inc.
 Iconic Therapeutics, Inc. BiotechnologyHealth Technology Iconic Therapeutics, Inc. engages in the development of novel therapeutics for the treatment of serious eye disorders. Its product ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of causes of blindness. The company was founded by Alan Garen, Kirk Dornbush, and Michael I. Sherman in 2003 and is headquartered in South San Francisco, CA. | 21 years |
| William Greene | M | - |
Iconic Therapeutics, Inc.
Iconic Therapeutics, Inc. BiotechnologyHealth Technology Iconic Therapeutics, Inc. engages in the development of novel therapeutics for the treatment of serious eye disorders. Its product ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of causes of blindness. The company was founded by Alan Garen, Kirk Dornbush, and Michael I. Sherman in 2003 and is headquartered in South San Francisco, CA. | 10 years |
| Ivor Royston | M | 79 | 8 years | |
| Bruce Robertson | M | 61 |
Iconic Therapeutics, Inc.
Iconic Therapeutics, Inc. BiotechnologyHealth Technology Iconic Therapeutics, Inc. engages in the development of novel therapeutics for the treatment of serious eye disorders. Its product ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of causes of blindness. The company was founded by Alan Garen, Kirk Dornbush, and Michael I. Sherman in 2003 and is headquartered in South San Francisco, CA. | 10 years |
| Sean Wirtjes | M | 54 | 6 years | |
| David Bruce Yoffie | M | 68 |
Harvard Business School
| 43 years |
| Julia Gregory | F | 71 |
Iconic Therapeutics, Inc.
Iconic Therapeutics, Inc. BiotechnologyHealth Technology Iconic Therapeutics, Inc. engages in the development of novel therapeutics for the treatment of serious eye disorders. Its product ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of causes of blindness. The company was founded by Alan Garen, Kirk Dornbush, and Michael I. Sherman in 2003 and is headquartered in South San Francisco, CA. | 7 years |
| Todd Foley | M | 52 |
Iconic Therapeutics, Inc.
Iconic Therapeutics, Inc. BiotechnologyHealth Technology Iconic Therapeutics, Inc. engages in the development of novel therapeutics for the treatment of serious eye disorders. Its product ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of causes of blindness. The company was founded by Alan Garen, Kirk Dornbush, and Michael I. Sherman in 2003 and is headquartered in South San Francisco, CA. | 10 years |
| K. Hirth | M | 72 |
Iconic Therapeutics, Inc.
Iconic Therapeutics, Inc. BiotechnologyHealth Technology Iconic Therapeutics, Inc. engages in the development of novel therapeutics for the treatment of serious eye disorders. Its product ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of causes of blindness. The company was founded by Alan Garen, Kirk Dornbush, and Michael I. Sherman in 2003 and is headquartered in South San Francisco, CA. | 9 years |
| Lonnie H. Norris | M | 81 |
Tufts University
| 44 years |
| Bambang Irawan Syah | M | - |
Cerca Insights Sdn. Bhd.
 Cerca Insights Sdn. Bhd. Miscellaneous Commercial ServicesCommercial Services Cerca Insights Sdn. Bhd. provides behavioral pharmacology paradigms to research institutes. It services include phenotyping new rodent models, sar support, identifying and optimising leads, behavioural assay development, PK screens and PD analysis, early safety assessment, ageing studies and chronic dosing. The company was founded by Anil K. Ratty in 2008 and is headquartered in Bayan Lepas, Malaysia. | - |
| Victoria Vezina | F | 56 | 4 years | |
| Dirk Sauer | M | 64 |
Iconic Therapeutics, Inc.
Iconic Therapeutics, Inc. BiotechnologyHealth Technology Iconic Therapeutics, Inc. engages in the development of novel therapeutics for the treatment of serious eye disorders. Its product ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of causes of blindness. The company was founded by Alan Garen, Kirk Dornbush, and Michael I. Sherman in 2003 and is headquartered in South San Francisco, CA. | 3 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Cynthia Tsai | F | 67 | 3 years | |
| Bob Haber | M | - |
Tufts University
| 5 years |
| Alexander Schmitz | M | 49 | 2 years | |
| Roger Krakoff | M | - |
Tufts University
| 2 years |
| Kenneth A. Sorensen | M | - | 4 years | |
| Stephen B. Blount | M | - |
Tufts University
| 7 years |
| Jamie Dimon | M | 68 |
Harvard Business School
Tufts University
| 7 years |
| Tony Ettinger | M | - |
Tufts University
| 5 years |
| Shukri Mohammed Imhemed Ghanem | M | 81 |
Tufts University
| 3 years |
| Thomas Allen | M | - |
Tufts University
| 6 years |
| Steven Koltai | M | - |
Tufts University
| 6 years |
| John Bunce | M | 65 |
Harvard Business School
| 2 years |
| Bruce Cohen | M | - |
Tufts University
Harvard Business School
| 7 years |
| Joseph J. Vallner | M | 76 | 2 years | |
| Stephen Finch | M | 66 |
Harvard Business School
| 2 years |
| Mark Gottfredson | M | 67 |
Harvard Business School
| 2 years |
| André François-Poncet | M | 64 |
Harvard Business School
| 2 years |
| Richard Berenson | M | - |
Harvard Business School
| 3 years |
| John Weinberg | M | 67 |
Harvard Business School
| 2 years |
| Steven J. Berger | M | - |
Harvard Business School
| 2 years |
| Jeffrey Edison | M | 63 |
Harvard Business School
| 2 years |
| Gary B. Olivar | M | 71 |
Harvard Business School
| 2 years |
| Mathew Welch | M | 60 |
Harvard Business School
| 2 years |
| Robert Glasspiegel | M | - |
Harvard Business School
| 2 years |
| Jean-Marc Daillance | M | 67 |
Harvard Business School
| 2 years |
| James van Bergh | M | - |
Harvard Business School
| 4 years |
| Tomonori Ito | M | 67 |
Harvard Business School
| 2 years |
| Dan Jick | M | - |
Harvard Business School
| 2 years |
| Peter Bisson | M | 67 |
Harvard Business School
| 2 years |
| Bonita Stewart | F | 66 |
Harvard Business School
| 2 years |
| Raymond Bachand | M | 76 |
Harvard Business School
| 3 years |
| Paul Theil | M | 71 |
Harvard Business School
| 2 years |
| Peter Ara Hrechdakian | M | 65 |
Harvard Business School
| 2 years |
| John Doll | M | - | - | |
| Ned Skinner | M | 71 |
Harvard Business School
| 2 years |
| Thomas R. Eisenmann | M | - |
Harvard Business School
| 2 years |
| Catalina Daniels | M | - |
Harvard Business School
| 10 years |
| Philippe Cyriel Elodie Haspeslagh | M | 74 |
Harvard Business School
| 3 years |
| Gary Olivar | M | 41 |
Harvard Business School
| - |
| Stephen Horn | M | - |
Harvard Business School
| 2 years |
| Bill McKenzie | M | - |
Harvard Business School
| 2 years |
| Louisa Wong | F | 66 |
Harvard Business School
| 2 years |
| John Seifrick | M | 64 |
Harvard Business School
| 4 years |
| JOHN KENNY | M | - |
Harvard Business School
| 2 years |
| Bruce Zimmerman | M | 66 |
Harvard Business School
| 2 years |
| Genjiro Miwa | M | - |
Harvard Business School
| 2 years |
| Süreyya Ciliv | M | 66 |
Harvard Business School
| 2 years |
| Dina Dublon | F | 70 |
Harvard Business School
| 2 years |
| Greg Melvin | M | - |
Harvard Business School
| 2 years |
| Curtis Feeny | M | 66 |
Harvard Business School
| 2 years |
| Theodore Samuels | M | 69 |
Harvard Business School
| 2 years |
| Roger Carolin | M | 68 |
Harvard Business School
| 2 years |
| Joseph Fuller | M | 67 |
Harvard Business School
| 2 years |
| Mark McDade | M | 69 |
Harvard Business School
| 2 years |
| Robert Black | M | 65 |
Harvard Business School
| 2 years |
| Dick Cashin | M | 70 |
Harvard Business School
| 2 years |
| Edwin C. Freeman | M | 68 |
Harvard Business School
| 2 years |
| Jeffrey D. Lamb | M | 66 |
Harvard Business School
| 2 years |
| John Walsh | M | 69 |
Harvard Business School
| 3 years |
| Lenore Sullivan | F | 66 |
Harvard Business School
| 2 years |
| Theo Melas-Kyriazi | M | 64 |
Harvard Business School
| 2 years |
| W. Kester | M | 73 |
Harvard Business School
| 41 years |
| Keith J. Krach | M | 66 |
Harvard Business School
| 2 years |
| Brion Blackwell Applegate | M | - |
Harvard Business School
| 2 years |
| Edward Bousa | M | 65 |
Harvard Business School
| 2 years |
| Daniel Levitan | M | 66 |
Harvard Business School
| 2 years |
| Hanif Dahya | M | 67 |
Harvard Business School
| 2 years |
| James L. Elrod | M | 69 |
Harvard Business School
| 2 years |
| Jonathan Ledecky | M | 66 |
Harvard Business School
| 2 years |
| Jimmy C. Lu | M | - |
Harvard Business School
| 2 years |
| David L. King | M | 68 |
Harvard Business School
| 2 years |
| Jill Greenthal | F | 67 |
Harvard Business School
| 2 years |
| Peter Craig Brockway | M | - |
Harvard Business School
| 2 years |
| Paul Rossetti | M | - |
Harvard Business School
| 2 years |
| Nicole Arnaboldi | F | 65 |
Harvard Business School
| 3 years |
| Mike Shanahan | M | - |
Harvard Business School
| 2 years |
| Kelt Kindick | M | 69 |
Harvard Business School
| 2 years |
| James Forbes Wilson | M | 66 |
Harvard Business School
| 2 years |
| Kathryn O'Neil | F | 60 |
Harvard Business School
| 4 years |
| Francis Joseph Conroy | M | - |
Harvard Business School
| 2 years |
| Sarah Stahl | F | - |
Harvard Business School
| 2 years |
| Andrew Bursky | M | 67 |
Harvard Business School
| 2 years |
| David Strohm | M | 75 |
Harvard Business School
| 2 years |
| Nancy Cooper | F | 70 |
Harvard Business School
| 2 years |
| Reinaldo Diaz | M | 70 |
Harvard Business School
| 2 years |
| Daniel Dickson | M | 72 |
Harvard Business School
| 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 99 | 99.00% |
| Malaysia | 1 | 1.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Bruce A. Cohen
- Personal Network
